Black Rock Inc. Neu Base Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.17 - $0.39 $340 - $781	2,003 Added 2.69%	76,372 $13,000
Q4 2022 Feb 13, 2023	BUY	$0.18 - $0.3 $224 - $374	1,247 Added 1.71%	74,369 $14,000
Q3 2022 Nov 14, 2022	SELL	$0.41 - $1.3 $851 - $2,700	-2,077 Reduced 2.76%	73,122 $29,000
Q2 2022 Aug 12, 2022	SELL	$0.82 - $1.93 $185 - $436	-226 Reduced 0.3%	75,199 $80,000
Q1 2022 May 12, 2022	SELL	$1.26 - $2.95 $3,889 - $9,106	-3,087 Reduced 3.93%	75,425 $141,000
Q4 2021 Feb 10, 2022	SELL	$2.6 - $4.18 $8,330 - $13,392	-3,204 Reduced 3.92%	78,512 $220,000
Q3 2021 Nov 09, 2021	SELL	$3.27 - $4.76 $17,128 - $24,932	-5,238 Reduced 6.02%	81,716 $295,000
Q2 2021 Aug 11, 2021	BUY	$4.63 - $7.34 $402,597 - $638,242	86,954 New	86,954 $416,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.